Shares of OR Royalties Inc. (NYSE:OR – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $38.25.
Several research firms recently commented on OR. Canaccord Genuity Group upgraded OR Royalties from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 22nd. Zacks Research lowered OR Royalties from a “strong-buy” rating to a “hold” rating in a report on Friday, December 19th. Wall Street Zen upgraded shares of OR Royalties from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 19th. Jefferies Financial Group reiterated a “hold” rating and issued a $38.00 target price on shares of OR Royalties in a research report on Sunday, December 7th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of OR Royalties in a research report on Monday, December 29th.
Get Our Latest Stock Analysis on OR
Hedge Funds Weigh In On OR Royalties
OR Royalties Stock Up 4.1%
OR stock opened at $40.29 on Friday. The stock has a market cap of $7.54 billion, a PE ratio of 51.00 and a beta of 0.76. The firm’s 50-day simple moving average is $38.07 and its 200 day simple moving average is $35.05. OR Royalties has a fifty-two week low of $17.55 and a fifty-two week high of $47.75.
OR Royalties (NYSE:OR – Get Free Report) last posted its earnings results on Wednesday, November 5th. The basic materials company reported $0.22 EPS for the quarter, topping the consensus estimate of $0.19 by $0.03. The firm had revenue of $71.63 million during the quarter, compared to analysts’ expectations of $53.85 million. OR Royalties had a net margin of 60.72% and a return on equity of 10.67%. Equities analysts forecast that OR Royalties will post 0.62 EPS for the current fiscal year.
OR Royalties Company Profile
OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.
The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.
Read More
- Five stocks we like better than OR Royalties
- Your Bank Account Is No Longer Safe
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- What a Former CIA Agent Knows About the Coming Collapse
- Ray Dalio Says Buy Gold. I Say Get Paid Every Month From It
- New gold price target
Receive News & Ratings for OR Royalties Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OR Royalties and related companies with MarketBeat.com's FREE daily email newsletter.
